Literature DB >> 6602167

Induction of cytotoxic T cell function requires sequential action of three different lymphokines.

D N Männel, W Falk, W Dröge.   

Abstract

Mesh:

Substances:

Year:  1983        PMID: 6602167

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  7 in total

1.  Resistance to metabolic inactivation is a functional phenotype of radioresistant stimulating spleen cells (RSCs) in allo-CTL generation.

Authors:  T Reme; C Cognot; A Dupuy d'Angeac
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

2.  Generation of cytotoxic T cells in the rat mixed lymphocyte reaction is blocked by monoclonal antibody MRC OX-8.

Authors:  J R Green
Journal:  Immunology       Date:  1984-06       Impact factor: 7.397

3.  The activity of lymphokines secreted by normal and malignant T cells.

Authors:  P H Krammer; U Hamann; L Hültner; B Kaltmann; U Kees; C Kubelka; D Gemsa
Journal:  Springer Semin Immunopathol       Date:  1984

4.  Methods for amplifying the induction and expression of cytotoxic response in vitro to syngeneic and autologous freshly-isolated solid tumors of mice.

Authors:  E Kedar; E Chriqui-Zeira; S Mitelman
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Characterization of soluble factors that induce the cytolytic activity and the expression of T cell growth factor receptors of a T cell hybrid.

Authors:  F Erard; P Corthesy; K A Smith; W Fiers; A Conzelmann; M Nabholz
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

6.  Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4).

Authors:  M B Widmer; R B Acres; H M Sassenfeld; K H Grabstein
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

7.  Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.

Authors:  G E Ranges; I S Figari; T Espevik; M A Palladino
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.